Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Sponsor
Peking Union Medical College Hospital
Study ID
NCT06674343
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Advanced or Metastatic Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    Furmonertinib 160mg, once daily, orally. Other Names: AST2818

Study Details

To evaluate the efficacy, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical mutations(19Del or L858R).

Key Dates

Start date
Jul 15, 2024
Status verified
Jul 2024
Primary completion
Dec 31, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
144 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib
    Furmonertinib 160mg, once daily, orally

Primary Outcome Measure

Progression Freae Survival (PFS) [ Time Frame: Approximately 24 months after the first patient begin study treatment ]

Related Studies